Skip to main content
Premium Trial:

Request an Annual Quote

Genmab, ACE BioSciences to Develop Antibody-based Fungicide

NEW YORK, Nov. 17 (GenomeWeb News) - Genmab and ACE BioSciences said today that they have agreed to develop an antibody-based fungicide against a protein target on Aspergillus fumigatus.

 

The arrangement is part of a broader drug development partnership between the companies under which ACE discovers novel protein targets in four disease areas and Genmab contributes its human antibody technology. The companies share costs and commercialization rights equally under the alliance, they said.

 

"ACE BioSciences's target discovery skills and Genmab's antibody development capabilities are an ideal combination for discovery and development of antibody based treatments for infectious diseases," Genmab CEO Lisa Drakeman said in a statement. "Fungal infections are becoming an increasingly urgent health threat and, despite not being adequately treated, currently represent a multi-billion dollar market."

 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.